No Data
No Data
Guobang Pharmaceutical (605507.SH): Zhejiang Minjin Henghua and Silk Road Fund reduced their holdings by a total of 1.82%
Gelonghui, May 8, 丨 Guobang Pharmaceutical (605507.SH) announced that it has received a “Notice Letter on the Progress of the Shareholding Reduction Plan and Changes in Equity by More than 1%” from Zhejiang Minjin Investment Henghua and Silk Road Fund. The current holdings reduction plan reduced the company's holdings by a total of 10,171,800 shares, with a change ratio of 1.82% of the company's total share capital. The amount of holdings reduction this time is over half. The current holdings reduction plan has not yet been implemented. After this change in equity, Zhejiang Mintou Henghua and Silk Road Fund held 20,887,083 shares of the company, accounting for 3.74% of the company's total share capital.
Guobang Pharmaceutical (605507.SH): A total of 3.468 million shares have been repurchased as of April 30
Gelonghui, April 30, 丨 Guobang Pharmaceutical (605507.SH) announced that as of April 30, 2024, the company had repurchased a total of 3.468 million shares through centralized bidding transactions. The repurchased shares accounted for 0.62% of the company's total share capital. The highest transaction price was 15.69 yuan/share, the lowest price was 13.05 yuan/share, and the total amount paid was 51.4603 million yuan (excluding transaction fees).
We Think Guobang Pharma (SHSE:605507) Is Taking Some Risk With Its Debt
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility of prices, but whether you will suffer a permanent loss of capital.' When we thi
Express News | Guobang Pharmaceutical: Shareholders holding 5% or more plan to reduce their holdings by no more than 3%
Guobang Pharmaceutical (605507.SH): Zhejiang Minjin Investment Henghua and Silk Road Fund plan to reduce their holdings by no more than 3%
Gelonghui, April 18 | Guobang Pharmaceutical (605507.SH) announced that due to their own capital requirements, shareholders Zhejiang Minjin Henghua and Silk Road Fund plan to reduce their holdings of the company's total shares by no more than 16,764,705 shares through centralized bidding and bulk transactions, with a reduction ratio of no more than 3% of the company's total share capital.
Guobang Pharmaceutical (605507.SH): Net profit in 2023 fell 33.49% year on year, and plans to pay 10 to 3 yuan
On April 15, Ge Longhui Pharmaceutical (605507.SH) released its 2023 annual report. During the reporting period, it achieved operating income of 5.349 billion yuan, a year-on-year decrease of 6.49%; net profit attributable to shareholders of listed companies was 612 million yuan, a year-on-year decrease of 33.49%; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 592 million yuan, a year-on-year decrease of 34.69%; and basic earnings per share were 1.10 yuan. It is proposed to distribute a cash dividend of RMB 3.00 (tax included) for every 10 shares to all shareholders.
No Data